Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Mobia Medical has planned an IPO for Mobia Medical, a medical devices business in the neurostimulation device sector in the United States, for $150 million. Mobia Medical develops the Vivistim System, a paired vagus nerve stimulation medical device for chronic ischemic stroke survivors with moderate to severe upper extremity impairments, with therapist activation during task-specific practice. The company supports at-home or daily-activity use to reinforce neural retraining, and it has implanted more than 1,000 Vivistim systems since launch. The other acquisition-style financing event is expected to offer 10 million shares at $14 to $16 per share, targeting net proceeds of about $134.5 million and up to $155.4 million with an underwriter option, to fund direct sales expansion of 83 professionals and operations for at least 12 months.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026